Dyne Therapeutics, Inc.
DYN
$25.70
-$0.26-1.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 78.15% | 53.14% | 35.25% | 29.66% | 70.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.89% | 2.37% | 19.59% | 7.79% | 60.91% |
| Operating Income | -56.89% | -2.37% | -19.59% | -7.79% | -60.91% |
| Income Before Tax | -61.07% | -4.76% | -25.03% | -11.24% | -70.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.07% | -4.76% | -25.03% | -11.24% | -70.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.07% | -4.76% | -25.03% | -11.24% | -70.28% |
| EBIT | -56.89% | -2.37% | -19.59% | -7.79% | -60.91% |
| EBITDA | -57.09% | -2.34% | -19.61% | -7.74% | -61.10% |
| EPS Basic | -10.86% | 30.23% | 13.62% | 20.87% | -38.34% |
| Normalized Basic EPS | -10.86% | 30.23% | 13.61% | 20.86% | -38.34% |
| EPS Diluted | -10.86% | 30.23% | 13.62% | 20.87% | -38.34% |
| Normalized Diluted EPS | -10.86% | 30.23% | 13.61% | 20.86% | -38.34% |
| Average Basic Shares Outstanding | 45.29% | 50.15% | 44.75% | 40.57% | 23.10% |
| Average Diluted Shares Outstanding | 45.29% | 50.15% | 44.75% | 40.57% | 23.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |